Hims and Hers Health Inc vs Mongodb Inc — how do they compare? Hims and Hers Health Inc trades at $30.6 (market cap $7.35B), while Mongodb Inc trades at $437.5 (market cap $33.51B). The key difference: Mongodb Inc is far larger — about 4.6× Hims and Hers Health Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals.
| HIMS | MDB | |
|---|---|---|
Market Cap | $7.35B | $33.51B |
Sector | Health | Technology |
52-Week High | $62.76 | $440.25 |
52-Week Low | $14.52 | $204.37 |
Enterprise Value | $7.73B | $31.12B |
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.
The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.
MongoDB (MDB) trades at $398.8, up 7.78% in the last session, reflecting strong momentum near the consensus price target of $400.39. The stock shows bullish technical signals with support at $384 and resistance at $407. Revenue growth is robust, reaching $2.01B in 2025, though the company remains unprofitable with a net margin of -1.12%. Recent quarters have consistently beaten EPS estimates, and analyst sentiment is overwhelmingly positive with 82% buy ratings.
The outlook for MDB is optimistic due to accelerating revenue growth and AI-driven demand, but risks include persistent losses, high valuation multiples, and competitive pressures. Institutional buying and bullish technical trends support near-term upside, yet profitability challenges warrant caution for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →